Ulcerative colitis (UC) is a chronic inflammatory condition involving the colon. Patients have abnormally increased thromboxane A2 (TXA2) production in their rectal mucosa, and in intestinal and peripheral blood mononuclear cells. Thromboxanes have proinflammatory effects. Ridogrel specifically inhibits the enzyme thromboxane synthetase and is accompanied by improvement in clinical disease activity in patients with active UC. This study will determine the safety and efficacy of low dose ridogrel for treatment of active UC.
Showing the most recent 10 out of 396 publications